Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation
Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation
复制标题
达拉他韦和阿舒瑞韦治疗肝移植后复发性丙型肝炎的结果
DOI：
10.1111/hepr.12853
复制
发表时间：
2017
影响因子：
4.2
通讯作者：
Inomata Y
中科院分区：
文献类型：
--
作者：
Honda M;Sugawara Y;Watanabe T;Tateyama M;Tanaka M;Uchida K;Kawabata S;Yoshii D;Miura K;Isono K;Hayashida S;Ohya Y;Yamamoto H;Sasaki Y;Inomata Y
目的直接作用口服药物的发展极大地改变了丙型肝炎病毒（HCV）感染的治疗策略。在这里，我们的目的是揭示达卡他韦（DCV）和阿舒那匹韦（ASV）的有效性和安全性的复发HCV基因型1型感染后肝transplantation（LT）.MethodsA回顾性研究进行了9例患者谁接受了24周的DCV/ASV治疗方案复发HCV基因型1型感染。五名患者是男性;四个失败的治疗与聚乙二醇干扰素（聚乙二醇干扰素）/利巴韦林，两个失败的simeprevir/聚乙二醇干扰素/利巴韦林，一个有耐药相关的变异Y 93 H在NS 5A区域，和一个接受维持dialys. ResultsMean时间开始治疗LT后70个月。在接受DCV/ASV治疗的9例患者中，8例（88.9%）在完成治疗后12周达到持续病毒应答（SVR 12）。病毒学失败的患者在接受DCV/ASV治疗方案前4个月接受西米泼维/聚乙二醇干扰素/利巴韦林治疗失败。此外，在DCV/ASV方案停药后，在患者中检测到NS 3区域的耐药相关变体D168 E。治疗期间他克莫司谷浓度有下降趋势，肾功能无显著变化。不良事件发生在两名患者（22.2%），但没有严重的不良事件发生在treatment.ConclusionsThe DCV/ASV方案是耐受性良好，导致高持续病毒应答率12周后完成治疗LT患者复发HCV基因型1型感染。
AimThe development of direct‐acting oral agents has dramatically changed the treatment strategy of hepatitis C virus (HCV) infection. Here we aimed to reveal the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) for recurrent HCV genotype 1 infection after liver transplantation (LT).MethodsA retrospective study was undertaken on nine patients who underwent a 24‐week DCV/ASV treatment regimen for recurrent HCV genotype 1 infection. Five of the patients were men; four had failed treatment with pegylated interferon (Peg‐IFN)/ribavirin, two had failed simeprevir/Peg‐IFN/ribavirin, one had the resistance‐associated variant Y93H in the NS5A region, and one underwent maintenance dialysis.ResultsMedian time to treatment initiation following LT was 70 months. Of the nine patients treated with DCV/ASV, eight (88.9%) achieved a sustained viral response 12 weeks after completion of therapy (SVR12). The patient with virologic failure had failed simeprevir/Peg‐interferon/ribavirin therapy 4 months before undergoing the DCV/ASV treatment regimen. In addition, a resistance‐associated variant D168E in the NS3 region was detected in the patient after discontinuation of the DCV/ASV regimen. The trough level of tacrolimus tended to decrease, and renal function showed no significant changes during treatment. Adverse events occurred in two patients (22.2%), but no severe adverse events occurred during treatment.ConclusionsThe DCV/ASV regimen was well tolerated, resulting in high rates of sustained viral response 12 weeks after completion of therapy for LT patients with recurrent HCV genotype 1 infection.
登录
查看更多内容
三例肝移植后丙型肝炎复发患者接受达拉他韦和阿舒瑞韦治疗：病例报告
影响因子：
4.2
作者：
T. Kawaoka;M. Imamura;Kei Morio;Yuki Nakamura;M. Tsuge;C. Nelson Hayes;Y. Kawakami;H. Aikata;H. Ochi;K. Ishiyama;K. Ide;H. Tashiro;H. Ohdan;K. Chayama
通讯作者：
K. Chayama
肝移植术后丙型肝炎病毒感染的抗病毒治疗
DOI：
--
发表时间：
2010
期刊：
Hepatitis Research and Treatment
影响因子：
--
作者：
Y. Sugawara;S. Tamura;N. Kokudo
通讯作者：
N. Kokudo
达卡他韦和阿舒瑞韦治疗患有严重胆汁淤积性丙型肝炎的肝移植受者安全有效
影响因子：
4.2
作者：
Y. Ueda;T. Kaido;E. Hatano;S. Ohtsuru;S. Uemoto
通讯作者：
S. Uemoto
活体肝移植中左叶难以维持肝流出但右叶难以维持
影响因子：
2.1
作者：
Y. Shirouzu;Y. Ohya;S. Hayashida;K. Asonuma;Y. Inomata
通讯作者：
Y. Inomata
肝移植后复发性丙型肝炎患者使用阿舒瑞韦和达拉他韦进行无干扰素治疗期间，他克莫司浓度暂时升高后浓度降低
影响因子：
3.1
作者：
Y. Ueda;S. Uemoto
通讯作者：
S. Uemoto